Antitumor activity and mechanisms of dual EGFR/DNA-targeting strategy for the treatment of lung cancer with EGFRL858R/T790M mutation
作者:Lumei Dai、Feng Qin、Yuying Xie、Bin Zhang、Zhijie Zhang、Sijia Liang、Fujia Chen、Xiaochao Huang、Hengshan Wang
DOI:10.1016/j.bioorg.2023.106510
日期:2023.6
fifteen 4-anilinoquinazoline derivatives bearing nitrogen mustard or hemi mustard moieties were designed and synthesized as dual EGFR-DNA targeting anticancer agents. Structures of target molecules were confirmed by 1H NMR, 13C NMR and HR-MS, and evaluated for their in vitro anti-proliferative activities using MTT assay. Compound 6g emerged as the most potent derivative against mutant-type H1975 cells
双靶点或多靶点 EGFR 抑制剂作为单一药物可以克服 EGFR 抑制剂耐药性并规避联合治疗的许多缺点。在这项工作中,设计并合成了 15 个带有氮芥或半芥部分的 4-苯胺基喹唑啉衍生物作为双 EGFR-DNA 靶向抗癌剂。目标分子的结构通过1 H NMR、13 C NMR 和 HR-MS确证,并使用 MTT 法评估其体外抗增殖活性。化合物6g成为针对突变型 H1975 细胞的最有效衍生物,IC 为50值为 1.45 μM,其效力比 Chl/Gef(苯丁酸氮芥和吉非替尼的等摩尔组合)强 4 倍。激酶抑制研究表明,6g对 EGFR L858R/T790M酶有极好的抑制作用,是吉非替尼的 8.6 倍。机理研究表明,6g以剂量依赖的方式诱导 H1975 细胞凋亡,并引起 DNA 损伤。重要的是,6g可显着抑制H1975细胞中p-EGFR及其下游p-AKT和p-ERK的表达。还进行了分子对接以深入了解EGFR